BioAge advances inflammaging drug into Phase 2

BioAge has begun iPhase 2 QUELL-CV trial, testing whether NLRP3 inhibition eases cardiovascular inflammatory burden. Inflammation has become something of a recurring character in geroscience. Whether researchers are studying cardiovascular disease, retinal disorders or neurodegeneration, the same chronic, low-grade immune activity keeps appearing in the background – less an innocent bystander than an increasingly persuasive […] The post BioAge advances inflammaging drug into Phase 2 appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.